Please assess the completion status of the following clinical trial:

Trial Title: Temsirolimus (Torisel) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients treated with Torisel (patients with metastatic and/or radically unresectable or advanced renal cell carcinoma).~Exclusion Criteria:~* Patients not administered Torisel.~* Patients with a history of severe hypersensitivity to temsirolimus, sirolimus derivative, or any of their components and/or derivatives.

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Temsirolimus (Type: None): Patients treated with Torisel (patients with metastatic and/or radically unresectable or advanced renal cell carcinoma)

Based on this trial design, predict the completion outcome and termination type (if applicable).